FOR RELEASE 2/1/2008, Friday
ROCHESTER, N.Y. — Bausch & Lomb, the global eye health company, announced today that it has completed its acquisition of eyeonics, inc.™, the rapidly growing, privately held ophthalmic medical device company headquartered in Aliso Viejo, Calif. Financial terms of the transaction were not disclosed.
Eyeonics now operates as a wholly-owned subsidiary of Bausch & Lomb. Its crystalens™ intraocular lens (IOL), the first and only U.S. Food and Drug Administration-approved accommodating IOL for the treatment of cataracts, joins Bausch & Lomb’s portfolio of innovative ophthalmic surgical products for cataract, vitreoretinal and refractive markets.
Nixon Peabody LLP acted as legal counsel to Bausch & Lomb. Wilson Sonsini Goodrich & Rosati acted as legal counsel to eyeonics, and Piper Jaffray & Co. served as a financial advisor to eyeonics.
# # #
About Bausch & Lomb
Bausch & Lomb is the eye health company dedicated to perfecting vision and enhancing life for consumers around the world. Its core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products. The Bausch & Lomb name is one of the best known and most respected healthcare brands in the world. Founded in 1853, the company is headquartered in Rochester, N.Y. With revenues in excess of $2 billion, it employs more than 13,000 people worldwide and its products are available in more than 100 countries. More information can be found at www.bausch.com.
Eyeonics and Crystalens are trademarks of Bausch & Lomb Incorporated.
The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.